BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial
Understanding the Role of Bilevel Positive Airway Pressure (BiPAP) in Pediatric Acute Asthma Exacerbations: A Prospective, Randomized, Double Blind, Controlled Trial
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Terminated
Interim Analysis showed futility for the primary outcome measure.
Other terminated trials from National Heart, Lung, and Blood Institute (NHLBI)
- Fracture of Radius and Ulna · Phase NA · Feb 2026
- Asthma · Aug 2025
- Acute Respiratory Failure · Phase PHASE3 · Jul 2025
- Aortic Valve Stenosis · Phase NA · Dec 2024
- Lymphangiectasia · Apr 2024
See all terminations from National Heart, Lung, and Blood Institute (NHLBI)
Listed as NCT05848115, this NA trial focuses on Asthma in Children and remains terminated or withdrawn. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Nov 2024 — Sep 2025 [monthly]
Recruiting NA
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Sep 2023 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jun 2023 — Sep 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .